Expert Rev Neurother. 2021 Jun 12. doi: 10.1080/14737175.2021.1942845. Online ahead of print.


INTRODUCTION: Mounting evidence has begun establishing a link between cannabis use and adverse psychotic outcomes in patients affected by psychosis. However, we have yet to determine if this relationship is maintained when controlling for important confounding variables. As such, the following systematic review aims to investigate if the association between cannabis use and psychotic outcomes (relapse or change in positive symptoms) is preserved when accounting for important confounding variables, and whether discontinued use mitigates any potential negative impacts.

AREA COVERED: The authors conducted an exhaustive search of the MEDLINE database and Google Scholar to identify articles pertaining to our systematic review. Thirty-three articles were retained for meeting the eligibility criteria.

EXPERT OPINION: Overall, the evidence confirms an overarching pattern of negative psychotic outcomes of cannabis intake in populations with psychosis, even when accounting for crucial confounding determinants. The authors recommend that psychosis patients be informed with evidence-based health information regarding the effects of cannabis use, as well as the potential benefits of cessation of use, on clinical outcomes. They also recommend that clinicians systematically evaluate cannabis intake patterns in psychosis patients and offer intervention services geared toward reducing problematic cannabis consumption. Researchers should record confounding factors (such as medication compliance) in a more systematic manner in future longitudinal investigations, while paying careful attention to the potency as well as the dose-response effects of the ingested cannabis. Finally, deciders will need to help investigate the potential impact of cannabis regulations on psychosis populations.

PMID:34120548 | DOI:10.1080/14737175.2021.1942845

Source: ncbi 2

Partage le savoir
Categories: Medical

error: Content is protected !!